Reserve Antibiotics: Defending The Ultimate Shield Against Resistant Microbes

Antimicrobial resistance (AMR) increases morbidity and mortality and makes common illnesses harder to treat, posing a serious danger to global health. Reserve antibiotics, which are crucial for managing severe infections caused by microbes resistant to several medicines, are categorized by the WHO as last-resort therapies. Novel beta-lactams, lipoglycopeptides, aminoglycosides and tetracycline derivatives are among the reserve antibiotics whose mechanisms, range and clinical uses are highlighted in this review. Their broad usage is limited by issues such toxicity, high costs, limited availability, risk of resistance arising and poor clinical trial evidence, despite their efficacy against resistance Both Gram-positive and Gram-negative pathogens. Emphasizing the importance of antimicrobial stewardship, precise diagnosis and equitable access, this article underscores the need for continued research and global coordination to sustain the efficacy of reserve antibiotics and combat the escalating AMR crisis.